1. Home
  2. CAPR vs BCML Comparison

CAPR vs BCML Comparison

Compare CAPR & BCML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • BCML
  • Stock Information
  • Founded
  • CAPR 2005
  • BCML 2004
  • Country
  • CAPR United States
  • BCML United States
  • Employees
  • CAPR N/A
  • BCML N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • BCML Major Banks
  • Sector
  • CAPR Health Care
  • BCML Finance
  • Exchange
  • CAPR Nasdaq
  • BCML Nasdaq
  • Market Cap
  • CAPR 324.6M
  • BCML 312.0M
  • IPO Year
  • CAPR N/A
  • BCML N/A
  • Fundamental
  • Price
  • CAPR $6.36
  • BCML $29.63
  • Analyst Decision
  • CAPR Strong Buy
  • BCML Strong Buy
  • Analyst Count
  • CAPR 8
  • BCML 1
  • Target Price
  • CAPR $24.75
  • BCML $32.00
  • AVG Volume (30 Days)
  • CAPR 1.2M
  • BCML 14.4K
  • Earning Date
  • CAPR 11-12-2025
  • BCML 10-16-2025
  • Dividend Yield
  • CAPR N/A
  • BCML 2.65%
  • EPS Growth
  • CAPR N/A
  • BCML 2.85
  • EPS
  • CAPR N/A
  • BCML 2.18
  • Revenue
  • CAPR $13,392,150.00
  • BCML $96,577,000.00
  • Revenue This Year
  • CAPR N/A
  • BCML $5.47
  • Revenue Next Year
  • CAPR $6,061.53
  • BCML $8.08
  • P/E Ratio
  • CAPR N/A
  • BCML $13.84
  • Revenue Growth
  • CAPR N/A
  • BCML N/A
  • 52 Week Low
  • CAPR $4.05
  • BCML $21.84
  • 52 Week High
  • CAPR $23.40
  • BCML $30.90
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.32
  • BCML 53.77
  • Support Level
  • CAPR $6.05
  • BCML $29.41
  • Resistance Level
  • CAPR $6.62
  • BCML $30.57
  • Average True Range (ATR)
  • CAPR 0.39
  • BCML 0.56
  • MACD
  • CAPR 0.05
  • BCML -0.08
  • Stochastic Oscillator
  • CAPR 47.89
  • BCML 14.77

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About BCML BayCom Corp

BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.

Share on Social Networks: